COHANCE - Cohance Lifesciences

Cohance Lifesciences

COHANCE · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti · MD: Venkateswarlu Jasti · Listing date: March 10, 2020 · Employees: 1114 · Hyderabad · http://www.suvenpharm.com

Stock Price vs Company Growth

1.0%

1.1%

22.2%

45.4%

46.6%

58.0%

6.2%

all

22.8%

🤔 How to analyze this graph?

Last Traded Price

₹ 536 1.0%

521

995

Company Overview

Sales

1,814 Cr

Growth: 25.6%

Profit after Tax

248 Cr

Growth: -20.6%

Mid Cap

20,525 Cr

P/E: 66.9x

Industry P/E: 33.1x

Fundamentals

Sales (Cr)	₹ 1,814
Growth	25.6%
EBITDA	23.4%
P/S	11.3x
Dividend	0.0%
P/E	66.9x
Book Value	₹ 47.9
PEG Ratio	2.6x
ROE	13.0%
P/B	11.2x

Shareholding Pattern

Institutions

Uti Small Cap Fund

2.17 %

L And T Mutual Fund Trustee Ltd-L And T Mid Cap Fund

1.95 %

Promoters

Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)

60.0 %

Others

Rambabu Chirumamilla

2.14 %

Qualified Institutional Buyer

0.7 %

Iepf

0.14 %

Increase Decrease No change

Company Profile Detailed

The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc.

Belongs to (27 Indices) view more

Investors (33)

landt.mu...

marshall...

rajarshi...

Followers (4)

ramakris...

krishna5...

venkatja...